Point of Focus Debate: For

Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis

By: Paul de Souza , Wei Chua, Stephen Clarke, David Goldstein and Chee Lee

EU Focus, Volume 2 Issue 4, October 2016, Pages 341-342

Published online: 01 October 2016

Abstract Full Text Full Text PDF (162 KB)

The cause is unclear for most renal cell cancers (RCCs), although inactivation of the von Hippel-Lindau tumor-suppressor gene plays a key role for some clear-cell variants. The resulting elevation of hypoxia-inducible factor and subsequent dysregulation of cell growth is well documented. The role of inflammation as a cause or promoter of cancer cell growth has been appreciated better in the laboratory than in the clinic, but in recent years the spotlight has turned to inflammation, fueled primarily by two observations: (1) recognition of the neutrophil/lymphocyte ratio (NLR) as a marker of inflammation for many cancers, including renal cancer [1] and [2]; and (2) the extraordinarily rapid development of PD1/L1 inhibitors [3], [4], and [5], which has highlighted the importance of immune function in some cancers. The biological mechanisms for the interplay between inflammation and immune function are still unclear, but there is increasing evidence that perturbations to many parts of the immune and inflammation signaling pathways aid in the promotion of angiogenesis and immune surveillance tolerance.

In the clinic, evaluation of systemic inflammation is difficult and there is no gold standard test. Elevated C-reactive protein (CRP), elevated erythrocyte sedimentation rate, hypoalbuminemia, thrombocytosis, and leukocytosis are clues to a systemic inflammatory response. Others are combinations of clinical factors, including NLR, and clinical scores such as the modified Glasgow Prognostic score are perhaps more sensitive tests of clinical information. For RCC, it has been shown that all of these measurements are statistically significant prognostic factors in settings such as the preoperative scenario [6], [7], [8], and [9] and metastatic RCC [10], [11], and [12]. Because NLR is cheap to measure and readily available, much evidence has emerged in the literature to support the hypothesis that inflammation is a key determinant of prognosis. Recent meta-analyses confirmed the prognostic value of NLR in RCC [10] and other solid tumors [13], as expected for a nonspecific driver of cancer cell fate. Presumably, NLR and other clinical markers of systemic inflammation represent nonspecific host responses to the presence of cancer.

However, whether there are specific inflammation-related gene products that drive the development or behavior of RCC is less clear; what data there are on this question appear to support the relationship. It was recently found that polymorphisms in MCP1 and its receptor CCR2, both major players in inflammation, were associated with RCC risk and prognosis [14]. Similarly, it was found that polymorphisms of CXC12 and CXCR4 had a significant influence on both the risk of RCC development and prognosis [15]. It has also been shown that intratumoral expression of P2X7, an ATP-gated plasma membrane ion channel, has prognostic significance for RCC patients [16].

However, not all potential markers of inflammation are necessarily related to RCC prognosis, nor are all cancers affected equally by the presence of inflammation. In a large population-based study, breast cancer prognosis appeared to be least influenced by systemic inflammation, whereas lung cancer was at the other extreme [17]. In histopathology specimens, CRP, a downstream mediator of interleukin 6, was associated with clear-cell RCC stage or grade, whereas cyclooxygenase enzyme 2, an important component of the eicosanoid pathway for the production of inflammatory lipid mediators, was not [18].

In summary, while there are still many questions to be answered with regard to the role of inflammation and its relationship to immune function and RCC tumor heterogeneity in determining an individual's prognosis, particularly whether there are specific inflammatory genes driving RCC outcomes, there is already strong clinical evidence that host inflammatory biomarkers such as NLR and others play an important role.

Conflicts of interest

The authors have nothing to disclose.


  • [1] Fox P, Hudson M, Brown C, et al. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer 2103;109:147–53.
  • [2] B. Cetin, V. Berk, M.A. Kaplan, et al. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2013;11:141-148 Crossref
  • [3] A. Gunturi, D.F. McDermott. Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol. 2014;15:137-146 Crossref
  • [4] K.M. Mahoney, P.D. Rennert, G.J. Freeman. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561-584 Crossref
  • [5] R.J. Motzer, B. Escudier, D.F. McDermott, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-1813
  • [6] A. Michigan, T.V. Johnson, V.A. Master. Preoperative C-reactive protein level adjusted for comorbidities and lifestyle factors predicts overall mortality in localized renal cell carcinoma. Mol Diagn Ther. 2011;15:229-234 Crossref
  • [7] C.S. Roxburgh, D.C. McMillan. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149-163 Crossref
  • [8] Y. Chang, H. An, L. Xu, et al. Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. Br J Cancer. 2015;113:626-633 Crossref
  • [9] G.W. Lamb, M. Aitchison, S. Ramsey, S.L. Housley, D.C. McMillan. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. Br J Cancer. 2012;106:279-283 Crossref
  • [10] K. Hu, L. Lou, J. Ye, S. Zhang. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. BMJ Open. 2015;5:e006404 Crossref
  • [11] D. Keizman, M. Ish-Shalom, P. Huang, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer. 2012;48:202-208
  • [12] S. Négrier, B. Escudier, F. Gomez, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie. Ann Oncol. 2002;13:1460-1468
  • [13] Y. Luo, D.L. She, H. Xiong, S.J. Fu, L. Yang. Pretreatment neutrophil to lymphocyte ratio as a prognostic predictor of urologic tumors: a systematic review and meta-analysis. Medicine. 2015;94:e1670
  • [14] G.X. Liu, X. Zhang, S. Li, R.D. Koiiche, J.H. Sindsceii, H. Song. Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma. Tumour Biol. 2013;34:2741-2746 Crossref
  • [15] C. Cai, L.H. Wang, Q. Dong, Z.J. Wu, M.Y. Li, Y.H. Sun. Association of CXCL12 and CXCR4 gene polymorphisms with the susceptibility and prognosis of renal cell carcinoma. Tissue Antigens. 2013;82:165-170 Crossref
  • [16] Z. Liu, Y. Liu, L. Xu, et al. P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma. Cancer Sci. 2015;106:1224-1231
  • [17] M.J. Proctor, D. Talwar, S.M. Balmar, et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer. 2010;103:870-876 Crossref
  • [18] S. Ali, Q. Yin-Goen, T.V. Johnson, et al. Expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma: correlation with pathological parameters in 110 patients. Tumour Biol. 2011;32:375-380 Crossref


School of Medicine, University of Western Sydney, Penrith, Australia

Corresponding author. School of Medicine, University of Western Sydney, Penrith, NSW 2751, Australia. Tel. +61 2 97726836; Fax: +61 2 97726880.

Place a comment

Your comment *

max length: 5000